65,437 trials
Healthy
Primary: Maximum Plasma Concentration (Cmax) — 9.26; 10.01 ng/mL
Healthy
Primary: Maximum Plasma Concentration (Cmax) — 2,246.58; 2,080.18; 2,278.46; 2,539.94 ng/mL
Nasolabial Folds
Primary: Procedural Pain Score — 2.0; 5.4 Units on a scale
Healthy
Primary: Maximum Plasma Concentration (Cmax) — 2,118.35; 4,236.70; 3,242.92 ng/mL
Asthma
Primary: Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at Week 12. — 5.2; 5.3; 7.7 Percent of predicted FEV1 — p=0.2696
Healthy
Primary: Maximum Plasma Concentration (Cmax) — 1.86; 1.96 ng/mL
Acne Vulgaris
Primary: Successful Outcome According to Investigator's Global Assessment (IGA) — 18; 19 participants — p=0.765
Pharmacokinetics
Primary: Maximum Plasma Concentration of Norethindrone With Colchicine at Steady State (Cmax, ss) — 24.17 ng/mL
Known or Suspected Focal Liver Lesions
Primary: Difference in Sensitivity of Lesion Detection in MRI Images (Post-contrast MRI Minus Pre-contrast MRI) Measured as Percentage Points — 8.65; 12.23; 7.50 Percentage points
Asthma
Primary: Change in Satisfaction With Asthma Treatment Questionnaire (SATQ) Scores From Baseline to the Mean of 3 Months and 6 Months After Patient Was Initially Treated With…
Acne Vulgaris
Primary: Cmax (ng/mL) at Day 1 — 0.10; 0.02 ng/mL
Kawasaki Disease
Primary: Number of Adverse Events (Focused on Side Effects From IVIG or Infliximab Administration) — 2; 3 events
Back Pain Without Radiation
Primary: Change From Baseline to Week 1 in Weekly Mean of the 24-hour Average Pain Scores — -0.54; -0.53; -0.71; -0.39 units on a scale — p=0.503
Hypersensitivity
Primary: Tooth Hypersensitity to Touch Stimuli (Tactile) — 10.83; 10.63 Units on a scale — p=0.05
Non-small Cell Lung Cancer
Primary: 2-Year Survival — 40.6; 55.7 percentage of participants